Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiu Feng Hu

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Expert Review of Anticancer Therapy|August 24, 2006
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinomaXiu Feng Hu, Eunice Yang, Jie Li, et al.
Acta Crystallographica. Section E, Structure Reports Online|March 14, 2012
Bis[4-amino-N-(pyrimidin-2-yl)benzene-sulfonamidato](1,10-phenanthroline)nickel(II)Xiu-Feng Hu, Yue Bing, Xing Li, et al.
World Journal of Gastroenterology|October 24, 2013
Pleiotrophin promotes perineural invasion in pancreatic cancerJun Yao, Xiu-Feng Hu, Xiao-Shan Feng, et al.
Experimental Hematology|August 26, 2009
Pim-1 expression and monoclonal antibody targeting in human leukemia cell linesJie Li, Xiu Feng Hu, Bruce E Loveland, et al.
The Journal of Clinical Investigation|January 17, 2009
PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosisXiu Feng Hu, Jie Li, Scott Vandervalk, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Expert Review of Anticancer Therapy|August 24, 2006
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinomaXiu Feng Hu, Eunice Yang, Jie Li, et al.
Acta Crystallographica. Section E, Structure Reports Online|March 14, 2012
Bis[4-amino-N-(pyrimidin-2-yl)benzene-sulfonamidato](1,10-phenanthroline)nickel(II)Xiu-Feng Hu, Yue Bing, Xing Li, et al.
World Journal of Gastroenterology|October 24, 2013
Pleiotrophin promotes perineural invasion in pancreatic cancerJun Yao, Xiu-Feng Hu, Xiao-Shan Feng, et al.
Experimental Hematology|August 26, 2009
Pim-1 expression and monoclonal antibody targeting in human leukemia cell linesJie Li, Xiu Feng Hu, Bruce E Loveland, et al.
The Journal of Clinical Investigation|January 17, 2009
PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosisXiu Feng Hu, Jie Li, Scott Vandervalk, et al.
Pageof 2